Pacific Edge Names Simon Flood Chairman Designate

Pacific Edge today announces the appointment of Mr Simon Flood as a Director and Chairman Designate.

Mr Flood is to replace Chris Gallaher who in September 2024 — at the invitation of Pacific Edge Directors — delayed his retirement until a successor was appointed. Mr Flood will join the Board today and will assume the role of Chairman at the conclusion of the next Board meeting on 18 December 2025.

Mr Flood brings a wealth of experience in business leadership and a global perspective on capital markets and investment management. He has held senior investment management and leadership roles in London, Hong Kong and Singapore with Mercury Asset Management, Axa Investment Management, Lion Global Investors and Merrill Lynch Investment Managers. He has also worked as an Executive Director at UK-based, technology-focused venture capital firm Imprimatur Capital.

Since returning to New Zealand in 2015, he has been appointed to several governance positions across a variety of sectors. He is currently Chairman of Queenstown Airport, a recent appointee to the Tertiary Education Commission, and several South Island organisations.

Pacific Edge Chair Chris Gallaher said: “We are delighted Simon has agreed to join the Board and take on the Chairman role. With Pacific Edge now in the strongest position yet to regain Medicare reimbursement of Cxbladder in the US, Simon’s deep understanding of capital markets and how to scale innovative technology businesses will be of enormous value to the company.

“I am meanwhile looking forward to my, long-delayed retirement. My confidence in the future of the company remains strong. I am delighted to be leaving the Board leadership of Pacific Edge in such capable hands and look forward to following, and as a shareholder sharing in, the company’s success.”

Mr Flood said: “I am looking forward to joining the Board and stepping into the Chairman role at the conclusion of the December Board meeting. Pacific Edge is the first mover and market leader in bladder cancer diagnostics offering clinical utility, patient satisfaction and economic value to healthcare payers around the world. This proposition is backed by the highest quality evidence and an ongoing robust evidence generation program that will entrench its leadership.

“The immediate challenge before the company is to overcome the restrictive decisions on Medicare coverage of Cxbladder. However, I share the Board’s view that with the landmark inclusion of Cxbladder Triage in the 2025 revision to the American Urological Association’s Microhematuria Guideline, that clinical and healthcare payer policy maker opinion is now turning in the company’s favor. This paves the way for a return to growth, and I am looking forward to working with my fellow Directors, Chief Executive Dr Peter Meintjes and his team through this next phase.”

Pacific Edge Independent Director Bryan Williams thanked Mr Gallaher for the support and leadership of the company through what has been one of the most challenging periods in the company’s history.

“Chris has over the last two years put the interests of Pacific Edge and its shareholders above his own, providing stability and confidence to its stakeholders amid the continued uncertainty over the Medicare coverage status for the company’s tests.

“With the appointment of Simon, and our Medicare Administrative Contractor Novitas convening an expert panel in February 2026 to consider the evidence and clinical opinion supporting the use of our tests, typically a step that precedes the opening of a new or substantially revised Medicare coverage determination, Chris leaves the company in a strong position. The Board, on behalf of shareholders, thanks him for his leadership of the company over the last nine years.”